{"protocolSection":{"identificationModule":{"nctId":"NCT04205006","orgStudyIdInfo":{"id":"SCFU"},"organization":{"fullName":"Medical University Innsbruck","class":"OTHER"},"briefTitle":"Stroke Card Long-term Follow-Up","officialTitle":"Long-term Outcome of a Pragmatic Trial of Multifaceted Intervention (STROKE-CARD Care) to Reduce Cardiovascular Risk and Improve Quality-of-life After Ischemic Stroke and Transient Ischemic Attack"},"statusModule":{"statusVerifiedDate":"2022-04","overallStatus":"ENROLLING_BY_INVITATION","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-12-16","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-11-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2022-11-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-12-13","studyFirstSubmitQcDate":"2019-12-18","studyFirstPostDateStruct":{"date":"2019-12-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-08-29","lastUpdatePostDateStruct":{"date":"2022-08-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Medical University Innsbruck","class":"OTHER"},"collaborators":[{"name":"VASCage GmbH","class":"OTHER"},{"name":"Tirol Kiniken GmbH","class":"OTHER"},{"name":"Barmherzige Brüder Vienna","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"We undertook the STROKE-CARD trial (NCT02156778) between 2014 and 2018 with follow-up until 2019 to evaluate the efficacy of the Post-Stroke disease-management program STROKE-CARD care. To further investigate the long-term efficacy of STROKE-CARD care all participants of the original trial will be invited for a Long-term in Person follow-up (3 - 6 years)."},"conditionsModule":{"conditions":["Ischemic Stroke","TIA"],"keywords":["ischemic stroke","secondary prevention","transient ischemic attack","disease management"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"bioSpec":{"retention":"SAMPLES_WITH_DNA","description":"Serum and whole blood sample."},"enrollmentInfo":{"count":1000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"STROKE CARD Cohort","description":"Consecutive patients treated at the Department of Neurology of the University Hospital Innsbruck with ischemic stroke or high-risk TIA between 2013 and 2018 and enrolled in the Stroke Card trial, (except for those who aborted the previous trial)."}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The composite CVD outcome: nonfatal stroke (ischemic or hemorrhagic)","description":"Recurrent stroke","timeFrame":"through study completion, an average of 4,5 years"},{"measure":"The composite CVD outcome: nonfatal myocardial infarction","description":"Major recurrent (post-discharge) cardiac event","timeFrame":"through study completion, an average of 4,5 years"},{"measure":"The composite CVD outcome: vascular death","description":"death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, cardiovascular procedures, and death due to other CV causes.","timeFrame":"through study completion, an average of 4,5 years"},{"measure":"self-reported health-related quality of life","description":"quantified with the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) overall health utility score14 with rescaled European visual analogue scale weights.","timeFrame":"through study completion, an average of 4,5 years"}],"secondaryOutcomes":[{"measure":"The composite outcome of stroke/TIA","description":"TIA defined as transient neurological deficit \\<24h and absence of DWI positive lesions on MRI","timeFrame":"through study completion, an average of 4,5 years"},{"measure":"all-cause mortality","description":"death from all causes","timeFrame":"through study completion at long term follow up visit, an average of 4,5 years"},{"measure":"EQ-ED-3L","description":"individual 3-level components of the European Quality of Life 5-Dimensions 3-Levels (EQ-5D-3L) questionnaire14 (i.e. mobility, self-care, usual activities, no pain or discomfort, no anxiety or depression) comparing people reporting no problems (level 1) with those reporting problems (level 2 and 3)","timeFrame":"through study completion at long term follow up visit, an average of 4,5 years"},{"measure":"Proportions of participants achieving target levels of risk factors in each trial arm of the previous STROKE-CARD trial.","description":"Blood pressure \\<140/\\<90 mmHg or \\<130/\\<85 mmHg in patients with diabetes mellitus, severe renal impairment; HbA1c \\<7.5% at the study visit in patients with diabetes mellitus; having quit smoking by the study visit in patients that had been smokers at baseline in the STROKE-CARD trial; LDL cholesterol \\< 100 mg/dL or \\<70 mg/dL in high-risk patients (i.e. stroke or TIA due to large-artery atherosclerosis or small-vessel occlusion, other evidence of atherosclerotic vascular disease, baseline diabetes; Metabolic Syndrome (NCEP-ATPIII): reduction of component number by 1, physical activity \\>90 minutes; Platelet inhibitor or oral anticoagulation; Oral anticoagulation (INR 2-3, Time in Therapeutic Range (TTR)\\>70%) in case of atrial fibrillation (AF), Lipid-lowering medication except for non-atherosclerotic strokes (e.g. vessel dissection).","timeFrame":"through study completion at long term follow up visit, an average of 4,5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Inclusion in the previous STROKE-CARD trial (NCT02156778)\n* Written informed consent\n\nExclusion Criteria:\n\n* none","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"All patients from the STROKE-CARD trial (n=2149) will be contacted by phone or mail for possible enrolment in the study. The STROKE-CARD cohort included consecutive patients with acute ischaemic stroke or TIA (ABCD2-Score ≥ 3) admitted to one of the two study centres (Medical University of Innsbruck, Hospital St. John's of God Vienna) between 2014 and 2018.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Stefan Kiechl, Prof. Dr.","affiliation":"Medical University of Innsbruck, Austria, Department of Neurology","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Wilfried Lang, Prof. Dr.","affiliation":"Hospital St. John's of God, Vienna, Austria, Department of Neurology","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Medical University of Innsbruck, Department of Neurology","city":"Innsbruck","state":"Tyrol","zip":"6020","country":"Austria","geoPoint":{"lat":47.26266,"lon":11.39454}},{"facility":"Hospital St. John's of God","city":"Vienna","zip":"1020","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}}]},"referencesModule":{"references":[{"pmid":"30400876","type":"RESULT","citation":"Toell T, Boehme C, Mayer L, Krebs S, Lang C, Willeit K, Prantl B, Knoflach M, Rumpold G, Schoenherr G, Griesmacher A, Willeit P, Ferrari J, Lang W, Kiechl S, Willeit J. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack -study protocol. BMC Neurol. 2018 Nov 6;18(1):187. doi: 10.1186/s12883-018-1185-2."},{"pmid":"31672716","type":"RESULT","citation":"Boehme C, Toell T, Mayer-Suess L, Domig L, Pechlaner R, Willeit K, Tschiderer L, Seekircher L, Willeit P, Griesmacher A, Knoflach M, Willeit J, Kiechl S. The dimension of preventable stroke in a large representative patient cohort. Neurology. 2019 Dec 3;93(23):e2121-e2132. doi: 10.1212/WNL.0000000000008573. Epub 2019 Oct 31."},{"pmid":"35915405","type":"DERIVED","citation":"Boehme C, Domig L, Komarek S, Toell T, Mayer L, Dejakum B, Krebs S, Pechlaner R, Bernegger A, Mueller C, Rumpold G, Griesmacher A, Vigl M, Schoenherr G, Schmidauer C, Ferrari J, Lang W, Knoflach M, Kiechl S. Long-term outcome of a pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack: study protocol. BMC Cardiovasc Disord. 2022 Aug 1;22(1):347. doi: 10.1186/s12872-022-02785-5."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5485","name":"Ischemic Attack, Transient","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T6034","name":"Quality of Life","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BXM","name":"Behaviors and Mental Disorders"}]}},"hasResults":false}